Companies Acrivon Therapeutics, Inc.
Acrivon Therapeutics (ACRV): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Acrivon Therapeutics, Inc.’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO pay, last three years
- $6,465,973FY2023
- $2,000,312FY2024
- $2,718,538FY2025
CEO total pay was $2,718,538 in fiscal 2025, up from $2,000,312 in fiscal 2024.
FY2025: salary $709,893 · bonus $0 · stock awards $0 · option awards $1,592,245
Executives and directors
Peter Blume-Jensen · CEOKristina Masson · EVPEric Devroe · COOCharles Baum, M.D., Ph.D · Independent DirectorDerek DiRocco, Ph.D · Independent DirectorIvana Magovčević-Liebisch, Ph.D., J.D · Independent DirectorMichael Tomsicek, M.B.A · Independent DirectorSanthosh Palani, Ph.D., CFA · Independent DirectorSharon Shacham, Ph.D., M.B.A · Independent Director
Frequently asked questions
Who was the highest-paid executive at Acrivon Therapeutics, Inc. in fiscal 2025?
As disclosed, Peter Blume-Jensen (Chief Executive Officer, President and Director) was the highest-paid executive at Acrivon Therapeutics, Inc. in fiscal 2025, with total compensation of $2,718,538.
How much does Acrivon Therapeutics, Inc. spend in total on board compensation for fiscal 2025?
As disclosed, Acrivon Therapeutics, Inc. reported total board compensation of $362,938 for fiscal 2025.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Peter Blume-Jensen | $709,893 | $0 | $0 | $1,592,245 | $410,400 | $0 | $6,000 | $2,718,538 |
| Chief Executive Officer, President and Director | ||||||||
| Kristina Masson | 594,472 | 0 | 0 | 573,206 | 251,248 | 0 | 6,000 | 1,424,926 |
| Executive Vice President, Business Operations, Director | ||||||||
| Eric Devroe | 528,745 | 0 | 0 | 573,206 | 250,052 | 0 | 6,000 | 1,358,003 |
| Chief Operating Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Peter Blume-Jensen | $2,718,538 | $2,000,312 | $6,465,973 | ↑ +718,226 |
| Kristina Masson | 1,424,926 | 1,197,176 | 739,783 | ↑ +227,750 |
| Eric Devroe | 1,358,003 | 1,146,728 | — | ↑ +211,275 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
Our current executive compensation program is intended to align executive compensation with our business objectives and to enable us to attract, retain and reward executive officers who contribute to our long-term success.
| CEO STI target (% of salary) | 60% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | — |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | — |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Peter Blume-Jensen | OPTION | — | — | — | — | — | $1,592,245 |
| Eric Devroe | OPTION | — | — | — | — | — | 573,206 |
| Kristina Masson | OPTION | — | — | — | — | — | 573,206 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Peter Blume-Jensen | $0 | $0 | $1,592,245 | 0.0% |
| Eric Devroe | 0 | 0 | 573,206 | 0.0% |
| Kristina Masson | 0 | 0 | 573,206 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Kristina Masson | RSU | 6,677 | — | $16,092 |
| Eric Devroe | RSU | 8,346 | — | 20,114 |
| Peter Blume-Jensen | RSU | 15,023 | — | 36,205 |
| Kristina Masson | RSU | 39,414 | — | 50,676 |
| Eric Devroe | RSU | 39,414 | — | 50,676 |
| Peter Blume-Jensen | RSU | 98,536 | — | 126,690 |
| Peter Blume-Jensen | RSU | 123,499 | — | 297,633 |
| Kristina Masson | Option | 140,540 | 5.31 | — |
| Eric Devroe | Option | 140,540 | 5.31 | — |
| Peter Blume-Jensen | Option | 390,390 | 5.31 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Santhosh Palani, Ph.D., CFAIndependent · Compensation · Nominating/Governance (Chair) | $57,500 | — | $17,870 | — | $42,938 | $118,308 |
| Charles Baum, M.D., Ph.DIndependent · Compensation (Chair) · Nominating/Governance | 60,000 | — | 17,870 | — | 0 | 77,870 |
| Michael Tomsicek, M.B.AIndependent · Audit (Chair) | 55,000 | — | 17,870 | — | 0 | 72,870 |
| Derek DiRocco, Ph.DIndependent · Audit · Nominating/Governance | 52,500 | — | 17,870 | — | 0 | 70,370 |
| Sharon Shacham, Ph.D., M.B.AIndependent · Compensation | 47,500 | — | 17,870 | — | 0 | 65,370 |
| Ivana Magovčević-Liebisch, Ph.D., J.DIndependent · Audit | 47,500 | 0 | 17,870 | 0 | 0 | 65,370 |
| Kristina Masson, Ph.D., M.B.AEmployee director | — | — | — | — | — | 0 |
| Peter Blume-Jensen, M.D., Ph.DEmployee director · Board Chair | — | — | — | — | — | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | $210,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 15,000 / 15,000 / 10,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $320,000 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $42,938 |
| Total cost of the board | $362,938 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Acrivon Therapeutics as a peer
Companies that benchmark against ACRV
2 companies name ACRV as a compensation peer
The list of companies that name ACRV as a peer is temporarily unavailable — recheck shortly.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Acrivon Therapeutics, Inc. | 2025 | Peter Blume-Jensen | $709,893 | $0 | $1,592,245 | $410,400 | $2,718,538 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-17 | — | — | — | — | — |
| 2025 | 2025-06-13 | — | — | — | — | — |
| 2024 | 2024-06-20 | — | — | — | — | — |
| 2023 | 2023-06-22 | — | — | — | — | — |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-06-17 | —a |
| 2025 | 2025-06-13 | —b |
| 2024 | 2024-06-20 | —c |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
c. Voting standard not stated in the filing.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | — |
|---|---|
| CEO total compensation | — |
| Median employee compensation | — |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Erick Gamelin | Chief Development Officer | 2026-05-14 | D | 404 | $2 | $776 | Common | Form 4 ↗ |
| Peter Blume-Jensen | Director | 2026-05-14 | D | 490 | 2 | 941 | Common, indirect | Form 4 ↗ |
| Katharine Peterson | Chief Accounting Officer | 2026-05-14 | D | 99 | 2 | 190 | Common | Form 4 ↗ |
| Peter Blume-Jensen | Director | 2026-05-14 | D | 1,253 | 2 | 2,406 | Common, indirect | Form 4 ↗ |
| Eric Devroe | Chief Operating Officer | 2026-05-14 | D | 613 | 2 | 1,177 | Common | Form 4 ↗ |
| Mary Miller | Chief Legal Officer | 2026-05-14 | D | 184 | 2 | 353 | Common | Form 4 ↗ |
| Peter Blume-Jensen | Director | 2026-05-18 | A | 72,706 | 0 | 0 | Common, indirect | Form 4 ↗ |
| Adam D. Levy | Chief Financial Officer | 2026-05-18 | A | 46,167 | 0 | 0 | Common | Form 4 ↗ |
| Derek DiRocco | Director | 2026-05-18 | A | 9,366 | 0 | 0 | Common, indirect | Form 4 ↗ |
| RA CAPITAL MANAGEMENT, L.P. | Director | 2026-05-18 | A | 9,366 | 0 | 0 | RSU | Form 4 ↗ |
| Erick Gamelin | Chief Development Officer | 2026-05-18 | A | 38,584 | 0 | 0 | Common | Form 4 ↗ |
| Ivana Magovcevic-Liebisch | Director | 2026-05-18 | A | 9,366 | 0 | 0 | Common | Form 4 ↗ |
| Santhosh Palani | Director | 2026-05-18 | A | 9,366 | 0 | 0 | Common | Form 4 ↗ |
| Peter Blume-Jensen | Director | 2026-05-18 | A | 180,095 | 0 | 0 | Common, indirect | Form 4 ↗ |
| Mansoor Raza Mirza | Chief Medical Officer | 2026-05-18 | A | 38,817 | 0 | 0 | Common | Form 4 ↗ |
| Sharon Shacham | Director | 2026-05-18 | A | 9,366 | 0 | 0 | Common | Form 4 ↗ |
| Charles M. Baum | Director | 2026-05-18 | A | 9,366 | 0 | 0 | Common | Form 4 ↗ |
| Katharine Peterson | Chief Accounting Officer | 2026-05-18 | A | 14,227 | 0 | 0 | Common | Form 4 ↗ |
| Michael John Tomsicek | Director | 2026-05-18 | A | 9,366 | 0 | 0 | Common | Form 4 ↗ |
| Eric Devroe | Chief Operating Officer | 2026-05-18 | A | 72,981 | 0 | 0 | Common | Form 4 ↗ |
| Mary Miller | Chief Legal Officer | 2026-05-18 | A | 49,830 | 0 | 0 | Common | Form 4 ↗ |
| Peter Blume-Jensen | Director | 2026-05-21 | D | 13,729 | 2 | 24,575 | Common, indirect | Form 4 ↗ |
| Charles M. Baum | Director | 2026-06-17 | A | 20,275 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| RA CAPITAL MANAGEMENT, L.P. | Director | 2026-06-17 | A | 20,275 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ivana Magovcevic-Liebisch | Director | 2026-06-17 | A | 20,275 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sharon Shacham | Director | 2026-06-17 | A | 20,275 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael John Tomsicek | Director | 2026-06-17 | A | 20,275 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Santhosh Palani | Director | 2026-06-17 | A | 20,275 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Derek DiRocco | Director | 2026-06-17 | A | 20,275 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mary Miller | Chief Legal Officer | 2026-07-21 | D | 573 | 2 | 1,008 | Common | Form 4 ↗ |
| Adam D. Levy | Chief Financial Officer | 2026-08-04 | D | 1,142 | 2 | 1,793 | Common | Form 4 ↗ |
| Peter Blume-Jensen | Director | 2026-08-18 | D | 484 | 2 | 973 | Common, indirect | Form 4 ↗ |
| Peter Blume-Jensen | Director | 2026-08-18 | D | 1,229 | 2 | 2,470 | Common, indirect | Form 4 ↗ |
| Eric Devroe | Chief Operating Officer | 2026-08-18 | D | 604 | 2 | 1,214 | Common | Form 4 ↗ |
| Erick Gamelin | Chief Development Officer | 2026-08-18 | D | 400 | 2 | 804 | Common | Form 4 ↗ |
| Mary Miller | Chief Legal Officer | 2026-08-18 | D | 185 | 2 | 372 | Common | Form 4 ↗ |
| Katharine Peterson | Chief Accounting Officer | 2026-08-18 | D | 101 | 2 | 203 | Common | Form 4 ↗ |
| Peter Blume-Jensen | Director | 2026-08-25 | D | 14,036 | 2 | 30,969 | Common, indirect | Form 4 ↗ |
| Michaela Levin | Chief Business Officer | 2026-08-31 | A | 130,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michaela Levin | Chief Business Officer | 2026-08-31 | A | 30,000 | 0 | 0 | Common | Form 4 ↗ |
| Mary Miller | Chief Legal Officer | 2026-10-05 | D | 294 | 2 | 585 | Common | Form 4 ↗ |
| Mary Miller | Chief Legal Officer | 2026-10-22 | D | 513 | 2 | 944 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (64 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Peter Blume-Jensen. DEF 14A, filed 2026-04-30. Section “Executive Compensation” · page 28. As printed: 2,718,538. View filing ↗
- Section 01, Kristina Masson. DEF 14A, filed 2026-04-30. Section “Executive Compensation”. As printed: 1,424,926. View filing ↗
- Section 01, Eric Devroe. DEF 14A, filed 2026-04-30. Section “Executive Compensation”. As printed: 1,358,003. View filing ↗
- Section 03, Peter Blume-Jensen OPTION. DEF 14A, filed 2026-04-30. Section “THE CLASSDIRECTOR NOMINEES LISTED BELOW. &” · grants of plan-based awards table. View filing ↗
- Section 03, Eric Devroe OPTION. DEF 14A, filed 2026-04-30. Section “THE CLASSDIRECTOR NOMINEES LISTED BELOW. &” · grants of plan-based awards table. View filing ↗
- Section 03, Kristina Masson OPTION. DEF 14A, filed 2026-04-30. Section “THE CLASSDIRECTOR NOMINEES LISTED BELOW. &” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. 10-K, filed 2026-03-19. Section “CEO Pay Ratio”. As printed: —. View filing ↗
- Section 08, Santhosh Palani, Ph.D., CFA. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 118,308. View filing ↗
- Section 08, Charles Baum, M.D., Ph.D. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 77,870. View filing ↗
- Section 08, Michael Tomsicek, M.B.A. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 72,870. View filing ↗
- Section 08, Derek DiRocco, Ph.D. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 70,370. View filing ↗
- Section 08, Sharon Shacham, Ph.D., M.B.A. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 65,370. View filing ↗
- Section 08, Ivana Magovčević-Liebisch, Ph.D., J.D. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 65,370. View filing ↗
- Section 08, Kristina Masson, Ph.D., M.B.A. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Peter Blume-Jensen, M.D., Ph.D. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Erick Gamelin 2026-05-14. Form 4, filed 2026-05-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Peter Blume-Jensen 2026-05-14. Form 4, filed 2026-05-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Katharine Peterson 2026-05-14. Form 4, filed 2026-05-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Peter Blume-Jensen 2026-05-14. Form 4, filed 2026-05-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Eric Devroe 2026-05-14. Form 4, filed 2026-05-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mary Miller 2026-05-14. Form 4, filed 2026-05-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Peter Blume-Jensen 2026-05-18. Form 4, filed 2026-05-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Adam D. Levy 2026-05-18. Form 4, filed 2026-05-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Derek DiRocco 2026-05-18. Form 4, filed 2026-05-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, RA CAPITAL MANAGEMENT, L.P. 2026-05-18. Form 4, filed 2026-05-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Erick Gamelin 2026-05-18. Form 4, filed 2026-05-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ivana Magovcevic-Liebisch 2026-05-18. Form 4, filed 2026-05-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Santhosh Palani 2026-05-18. Form 4, filed 2026-05-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Peter Blume-Jensen 2026-05-18. Form 4, filed 2026-05-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mansoor Raza Mirza 2026-05-18. Form 4, filed 2026-05-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sharon Shacham 2026-05-18. Form 4, filed 2026-05-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Charles M. Baum 2026-05-18. Form 4, filed 2026-05-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Katharine Peterson 2026-05-18. Form 4, filed 2026-05-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael John Tomsicek 2026-05-18. Form 4, filed 2026-05-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Eric Devroe 2026-05-18. Form 4, filed 2026-05-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mary Miller 2026-05-18. Form 4, filed 2026-05-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Peter Blume-Jensen 2026-05-21. Form 4, filed 2026-05-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Charles M. Baum 2026-06-17. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, RA CAPITAL MANAGEMENT, L.P. 2026-06-17. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ivana Magovcevic-Liebisch 2026-06-17. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sharon Shacham 2026-06-17. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael John Tomsicek 2026-06-17. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Santhosh Palani 2026-06-17. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Derek DiRocco 2026-06-17. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mary Miller 2026-07-21. Form 4, filed 2026-07-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Adam D. Levy 2026-08-04. Form 4, filed 2026-08-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Peter Blume-Jensen 2026-08-18. Form 4, filed 2026-08-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Peter Blume-Jensen 2026-08-18. Form 4, filed 2026-08-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Eric Devroe 2026-08-18. Form 4, filed 2026-08-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Erick Gamelin 2026-08-18. Form 4, filed 2026-08-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mary Miller 2026-08-18. Form 4, filed 2026-08-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Katharine Peterson 2026-08-18. Form 4, filed 2026-08-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Peter Blume-Jensen 2026-08-25. Form 4, filed 2026-08-27. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michaela Levin 2026-08-31. Form 4, filed 2026-09-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michaela Levin 2026-08-31. Form 4, filed 2026-09-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mary Miller 2026-10-05. Form 4, filed 2026-10-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mary Miller 2026-10-22. Form 4, filed 2026-10-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-06-17. Item 5.07 · say-on-pay result. As reported: —. View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-06-13. Item 5.07 · say-on-pay result. As reported: —. View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-06-21. Item 5.07 · say-on-pay result. As reported: —. View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 320,000 + equity 0 + all other 42,938 = 362,938, summed across the director compensation table rows.
- Acrivon Therapeutics, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Acrivon Therapeutics, Inc.'s own proxy. As printed: 2,718,538. View filing ↗